These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23035873)

  • 1. Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding.
    Kandane-Rathnayake RK; Isbister JP; Zatta AJ; Aoki NJ; Cameron P; Phillips LE;
    ANZ J Surg; 2013 Mar; 83(3):155-60. PubMed ID: 23035873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
    Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
    Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
    Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
    Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of outcome in Jehovah's Witness patients in cardiac surgery: an Australian experience.
    Bhaskar B; Jack RK; Mullany D; Fraser J
    Heart Lung Circ; 2010 Nov; 19(11):655-9. PubMed ID: 20813584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
    Sniecinski RM; Chen EP; Levy JH; Szlam F; Tanaka KA
    Anesth Analg; 2007 Apr; 104(4):763-5. PubMed ID: 17377078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of outcomes following recombinant activated FVII use for refractory bleeding during abdominal aortic aneurysm repair.
    Kandane-Rathnayake RK; Willis CD; Beiles CB; Bourke BM; Cameron PA; McCall P; Phillips LE
    Eur J Vasc Endovasc Surg; 2013 Jun; 45(6):617-25. PubMed ID: 23433950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
    Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
    Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation.
    Jabbour N; Gagandeep S; Peilin AC; Boland B; Mateo R; Genyk Y; Selby R; Zeger G
    Am Surg; 2005 Feb; 71(2):175-9. PubMed ID: 16022020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma.
    Goldberg R; Drummond KJ
    J Clin Neurosci; 2008 Oct; 15(10):1164-6. PubMed ID: 17702584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
    Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
    Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in the use of recombinant activated factor VII in critical bleeding.
    Willis CD; Cameron PA; Phillips L
    Intern Med J; 2010 Jul; 40(7):486-93. PubMed ID: 19712199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
    Flower O; Phillips LE; Cameron P; Gunn K; Dunkley S; Watts A; Rajbhandari D
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):207-15. PubMed ID: 20182351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mortality after high-risk surgery in Jehovah's Witness patients].
    Habler O; Thörner M; Schmidt C; Hofmann P; Döbert U; Höhler M; Klingler S; Moog S; Oehme A; Schäufele M; Wege C; Voß B
    Anaesthesist; 2019 Jul; 68(7):444-455. PubMed ID: 31236704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
    Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
    Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia.
    Virchis A; Hughes C; Berney S
    Hematol J; 2004; 5(3):281-2. PubMed ID: 15167918
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of recombinant activated factor VII in a Jehovah's Witness patient.
    Hsieh A; Cheong I
    Am J Emerg Med; 2007 Nov; 25(9):1085.e1-2. PubMed ID: 18022514
    [No Abstract]   [Full Text] [Related]  

  • 17. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.
    Zatta A; Mcquilten Z; Kandane-Rathnayake R; Isbister J; Dunkley S; Mcneil J; Cameron P; Phillips L
    Blood Transfus; 2015 Jan; 13(1):86-99. PubMed ID: 24960661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.
    Diringer MN; Ferran JM; Broderick J; Davis S; Mayer SA; Steiner T; Brun NC; Skolnick BE; Christensen MC
    Cerebrovasc Dis; 2007; 24(2-3):219-25. PubMed ID: 17630481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripartum Care of the Jehovah's Witness Patient.
    Riveros-Perez E; Kacmar R
    Clin Obstet Gynecol; 2017 Jun; 60(2):394-404. PubMed ID: 28121643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.